Doximity (DOCS) stock saw major gains on Friday, even after the company posted Fiscal Q1 2027 earnings results that were mixed compared to Wall Street’s estimates. That included adjusted earnings per share of 29 cents, compared to Wall Street’s estimate of 30 cents. However, revenue of $156.6 million was above analysts’ estimates of $151.73 million.
Instead of focusing on earnings results, investors are taking in the company’s AI growth. Doximity reported that Doximity Asks, its clinical AI assistant, was the top-performing model in the U.S., based on the NOHARM benchmark. In addition to that, the company reported another quarter of record engagement for Doximity Asks.
Jeff Tangney, co-founder and CEO of Doximity, said, “In Q1 we had accelerated revenue growth along with workflow active prescriber growth of more than 30% year-over-year and AI Search query growth of over 25% quarter-over-quarter.”
DOCS stock saw an incredible 60.94% jump on Friday, but was still down 24.91% year-to-date. The shares have also fallen 68.97% over the past 12 months. This movement came with heavy trading activity, as some 19.7 million shares changed hands, versus a three-month average daily trading volume of about 3.11 million shares.
Morgan Stanley Praises Doximity Stock
Four-star Morgan Stanley analyst Craig Hettenbach came out in support of Doximity after the company’s earnings report. He noted the “solid” Q1 results and said that AI search momentum is building faster than he expected. However, he called the company’s guidance “mixed.”
To go along with those comments, the Morgan Stanley analyst reiterated an Outperform rating and a $35 price target for DOCS stock. That price target represents a potential 5.26% upside for the shares.
Is Doximity Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Doximity is Moderate Buy, based on seven Buy, 12 Hold, and one Sell rating over the past three months. With that comes an average DOCS stock price target of $27.76, representing a potential 16.5% downside for the shares. These ratings and price targets will likely change as analysts update their coverage after today’s earnings report. (See DOCS Stock Forecast)



